CDK4/6激活的非侵入性PET成像在乳腺癌中的应用
研究开发了18F标记的CDK4/6抑制剂(18F-CDKi)作为新型PET显像剂,用于定量雌激素受体(ER)阳性、人表皮生长因子受体2(HER2)阴性乳腺癌中CDK4/6表达。在MCF-7细胞系和荷瘤小鼠中评估了其体内外生物学特异性,结果显示18F-CDKi具有高放射化学纯度、稳定性和特异性靶向亲和力,肿瘤摄取约4%ID/g,可被冷palbociclib阻断。结论认为18F-CDKi是首个18F PET CDK4/6显像剂,有望用于ER阳性、HER2阴性乳腺癌成像。
要点
- 18F-CDKi放射化学纯度>98%,合成总时间70分钟。
- 细胞摄取10分钟达约65%,冷palbociclib阻断后降至<5%。
- 荷瘤小鼠肿瘤摄取约4%ID/g,50倍冷palbociclib降至约0.3%ID/g。
核心结论
- 18F-CDKi是首个18F PET CDK4/6显像剂,对ER阳性、HER2阴性乳腺癌具有 promising 成像潜力。
研究设计与样本
- 研究合成了18F-CDKi,并在MCF-7细胞系和荷MCF-7乳腺癌小鼠模型中评估其体内外生物学特异性。
- 采用非放射性palbociclib作为阻断剂研究18F-CDKi的结合特异性和选择性。
主要发现
- 18F-CDKi总放射化学未校正产率为15%,放射化学纯度高于98%,合成至最终可注射制剂总时间70分钟。
- 18F-CDKi与19F-CDKi共注射的高压液相色谱保留时间为27.4分钟;体内血液半衰期(加权)为7.03分钟,辛醇/水分配系数为1.91±0.24,显示主要亲脂性。
- 18F-CDKi在体外和体内稳定(注射后4小时>98%),并保持对CDK4/6的强效靶向亲和力。
- MCF-7细胞摄取实验显示特异性摄取,孵育后10分钟细胞内浓度最高约65%;与摩尔过量palbociclib共孵育时摄取降至<5%。
- ER阳性、HER2阴性MCF-7乳腺癌模型的体内成像和离体生物分布显示肿瘤特异性摄取约4%ID/g(50倍冷palbociclib存在下降至约0.3%);全面生物分布分析显示非靶器官中CDK4/6激活显著较低。
临床怎么用
- 18F-CDKi PET成像可用于无创定量ER阳性、HER2阴性乳腺癌中CDK4/6表达,辅助评估CDK4/6激活状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cell cycle is a progression of 4 distinct phases (G1, S, G2, and M), with various cycle proteins being essential in regulating this process. We aimed to develop a radiolabeled cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for breast cancer imaging. Our transfluorinated analog (18F-CDKi) was evaluated and validated as a novel PET imaging agent to quantify CDK4/6 expression in estrogen receptor (ER)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods:18F-CDKi was synthesized and assayed against CDK4/6 kinases. 18F-CDKi was prepared with a 2-step automated synthetic strategy that yielded the final product with remarkable purity and molar activity. In vitro and in vivo biologic specificity was assessed in a MCF-7 cell line and in mice bearing MCF-7 breast tumors. Nonradioactive palbociclib was used as a blocking agent to investigate the binding specificity and selectivity of 18F-CDKi. Results:18F-CDKi was obtained with an overall radiochemical uncorrected yield of 15% and radiochemical purity higher than 98%. The total time from the start of synthesis to the final injectable formulated tracer is 70 min. The retention time reported for 18F-CDKi and 19F-CDKi is 27.4 min as demonstrated by coinjection with 19F-CDKi in a high-pressure liquid chromatograph. In vivo blood half-life (weighted, 7.03 min) and octanol/water phase partition coefficient (1.91 ± 0.24) showed a mainly lipophilic behavior. 18F-CDKi is stable in vitro and in vivo (>98% at 4 h after injection) and maintained its potent targeting affinity to CDK4/6. Cellular uptake experiments performed on the MCF-7 breast cancer cell line (ER-positive and HER2-negative) demonstrated specific uptake with a maximum intracellular concentration of about 65% as early as 10 min after incubation. The tracer uptake was reduced to less than 5% when cells were coincubated with a molar excess of palbociclib. In vivo imaging and ex vivo biodistribution of ER-positive, HER2-negative MCF-7 breast cancer models showed a specific uptake of approximately 4% injected dose/g of tumor (reduced to ∼0.3% with a 50-fold excess of cold palbociclib). A comprehensive biodistribution analysis also revealed a significantly lower activation of CDK4/6 in nontargeting organs. Conclusion:18F-CDKi represents the first 18F PET CDK4/6 imaging agent and a promising imaging agent for ER-positive, HER2-negative breast cancer.
引用
- Ramos N, Baquero-Buitrago J, Ben Youss Gironda Z, et al. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. J Nucl Med. 2019. PMID: 31481582. doi:10.2967/jnumed.119.232603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。